IRVING, Texas -- Adam Scott and Trevor Immelman were named this week’s AstraZeneca Charity Challenge winners for their first-place standing entering the final round of the EDS Byron Nelson Championship. The AstraZeneca Charity Challenge, formerly known as the CRESTOR® Charity Challenge, is a season-long competition that recognizes and rewards the tournament leader entering the final round at 35 PGA TOUR events. Through the sponsorship, AstraZeneca will donate $3.5 million this year to designated health care charities and will have donated a three-year total of $9.7 million by the conclusion of the 2006 PGA TOUR season.

For Immelman’s and Scott’s performance, AstraZeneca will donate $100,000 to the American Heart Association (AHA), on behalf of Immelman, Scott and the EDS Byron Nelson Championship. The funds will be split evenly between the AHA’s national headquarters, located in Dallas, and the South Florida chapter.

“AstraZeneca’s commitment to save lives means a great deal the American Heart Association & American Stroke Association, especially in helping to sustain our community outreach programs,” says Cass Wheeler, Chief Executive Officer. “This generous gift will provide the financial support for continued work toward the AHA’s goal of a 25% reduction in heart disease and stroke by the year 2010.”

AstraZeneca produces a wide range of products that make significant contributions to treatment options and patient care including CRESTOR, NEXIUM, SEROQUEL, ARIMIDEX, and PULMICORT RESPULES. Through this year’s sponsorship, as part of its commitment to patient health and well being, AstraZeneca will also designate health care related charities across therapeutic areas as recipients at the 35 PGA TOUR events throughout the year.

“AstraZeneca’s partnership with the PGA TOUR is an integral part of our mission of giving back in local communities throughout America,” said Tony Zook, CEO, AstraZeneca U.S. “The AstraZeneca Charity Challenge offers a unique platform for providing important disease awareness, health information and education to make a difference in the lives of patients and consumers everyday.”

The AstraZeneca Charity Challenge is the centerpiece of a multi-year PGA TOUR partnership with AstraZeneca (NYSE:AZN). Last year, AstraZeneca donated $3.5 million through the program. Highlights from the AZCC include:
• Last week, the AstraZeneca Charity Challenge winner at the Wachovia Championship was Jim Furyk, his second AstraZeneca Charity Challenge victory of 2006.
•  At 15 of the first 16 tournaments of 2006, and 12 consecutive, the AstraZeneca Charity Challenge winner or co-winner went on to win the tournament.
• More than 85 charities have benefited from the program.
• Vijay Singh leads all players with eight AstraZeneca Charity Challenge wins. With some of his charitable “winnings,” Singh donated money to the American Red Cross Hurricane Relief Funds in Florida and New Orleans.

• Other multiple winners have included Tom Lehman, Phil Mickelson, Jim Furyk (four), Stuart Appleby, Chad Campbell, Luke Donald, Sergio Garcia, Rod Pampling, Adam Scott and David Toms (three), and the following players who triumphed twice: Bart Bryant, Chris DiMarco, Arron Oberholser, Joe Ogilvie, Kenny Perry, Carl Pettersson, Ted Purdy and Tiger Woods.

Fans can log on to www.astrazeneca.pgatour.com to read about past AstraZeneca Charity Challenge winners and learn more about AstraZeneca.

About the American Heart Association
Since 1924, the American Heart Association has helped protect people of all ages and ethnicities from the ravages of heart disease and stroke. These diseases, the nation's No. 1 and No. 3 killers, claim more than 930,000 American lives a year. The association invested more than $407 million in fiscal year 2002-03 for research, professional and public education, advocacy and community service programs so people across America can live stronger, longer lives. Visit the American Heart Association at www.americanheart.org or call 1-800-AHA-USA-1 (1-800-242-8721).

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. Worldwide, AstraZeneca has six major research and development sites, four discovery facilities and a clinical research site. In total, AstraZeneca’s R&D organization is comprised of more 11,500 people located in seven countries including Canada, France, India, Japan, Sweden, United Kingdom and the United States.